Regeneron Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Regeneron Pharmaceuticals

30/07/2026 17:28

Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $14.29​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $12.89.  The mean expectation of twenty two analysts for the quarter was for earnings of $10.26 per share. Wall Street expected results to range from $7.64  to $12.33 per share.
Revenue rose 16.7% to $4.29 billion from a year ago; analysts expected $3.82 billion. 
Regeneron Pharmaceuticals Inc's reported EPS for the quarter was $12.23​.
The company reported quarterly net income of $1.3 billion.
Regeneron Pharmaceuticals Inc shares had risen by 11.5% this quarter and lost 9.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.7% in the last three months.​ 
In the last 30 days, fourteen analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Regeneron Pharmaceuticals Inc is $816.79, about 14.9% above its last closing price of $695.42
This summary was machine generated from LSEG data July 30 at 04:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
10.26
14.29
Beat
Mar. 31 2026 
8.94
9.47
Beat
Dec. 31 2025 
10.62
11.44
Beat
Sep. 30 2025 
9.59
11.83
Beat